The Medtronic MiniMed Insulin Pump lawsuit centers on allegations that certain insulin pumps contained defects that could interfere with the safe delivery of insulin to diabetic patients.
Designed to reduce the need for frequent insulin injections, MiniMed pumps use an insulin reservoir and infusion system to provide continuous insulin therapy throughout the day.
In November 2019, medical device company Medtronic announced a safety notification involving MiniMed 630G and 670G insulin pumps after identifying problems associated with a defective retainer ring that secures the insulin cartridge within the pump.
According to the FDA, a damaged, broken, or missing retainer ring could cause the pump to deliver too much insulin or too little insulin, creating a reasonable probability of serious adverse health consequences.
Federal regulators later classified the action as a Class I recall, the FDA’s most serious recall designation.
At the time of the recall, the FDA reported 26,421 complaints involving the malfunction, including 2,175 reported injuries and at least one death.
Plaintiffs claim these defects exposed users to dangerous blood sugar fluctuations, diabetic emergencies, hospitalization, and other severe complications.
The following timeline outlines key regulatory actions, recalls, and developments that contributed to the Medtronic MiniMed Insulin Pump litigation:
- September 2016: The FDA approved the MiniMed 670G, the first hybrid closed-loop insulin delivery system marketed as a major advancement in diabetes management.
- November 2019: Medtronic notified customers about the risk of broken or missing retainer rings in certain MiniMed 630G and 670G pumps.
- February 2020: The FDA designated the recall as a Class I recall affecting more than 322,000 devices in the United States.
- 2021: The FDA issued a warning letter criticizing aspects of Medtronic’s handling of the defect and recall process.
- 2024: Additional FDA safety actions addressed battery-related issues affecting MiniMed 600 and 700 series pumps that could interrupt insulin delivery.
Recent lawsuits continue to focus on injuries allegedly caused by insulin overdelivery, insulin underdelivery, and pump failures that interrupted treatment for patients living with chronic conditions.
Depending on the circumstances, reported complications include severe hypoglycemia, hyperglycemia, diabetic ketoacidosis, seizures, diabetic coma, and death caused by uncontrolled blood glucose levels.
As litigation continues to develop, individuals who experienced serious complications after using recalled MiniMed pumps may have grounds to pursue compensation for their injuries and related losses.
FDA Investigation Into MiniMed Insulin Pumps
Federal regulators began scrutinizing certain MiniMed insulin pumps after receiving thousands of reports involving retainer ring failures that could affect insulin delivery.
The investigation focused on MiniMed 630G and 670G pumps equipped with a clear ring designed to secure the insulin cartridge inside the pump reservoir compartment.
According to the FDA, a cracked, damaged, or faulty retainer ring could allow the insulin reservoir to become improperly seated, potentially causing users to receive too much insulin, too little insulin, or no insulin at all.
Those failures created a risk of life-threatening medical emergencies, including severe hypoglycemia, hyperglycemia, diabetic ketoacidosis, seizures, coma, and death.
In November 2019, Medtronic issued a safety notification advising customers to inspect their pumps for retainer ring damage and seek a replacement device if the component appeared loose, broken, or missing.
Several months later, the FDA classified the action as a Class I recall, the agency’s most serious recall designation, reserved for situations involving a reasonable probability of serious injury or death.
At the time, federal regulators reported more than 26,000 complaints associated with the defect, including over 2,000 injuries and at least one death linked to the recalled pumps.
The FDA’s concerns extended beyond the defect itself.
In a 2021 warning letter, the agency criticized aspects of Medtronic’s complaint handling, risk assessments, and corrective actions related to MiniMed pump failures.
FDA investigators noted that Medtronic had opened an internal corrective and preventive action process years before the recall and had received tens of thousands of complaints involving retainer ring damage.
Those findings have become a central part of the factual background surrounding MiniMed litigation, with plaintiffs alleging that users were exposed to preventable risks before adequate corrective measures were implemented.
Which MiniMed Pumps Have Been Recalled?
Several MiniMed insulin pumps have been the subject of FDA recall actions over the past several years.
The most significant recall associated with the current litigation involved certain 600 series insulin pumps that contained a retainer ring defect capable of affecting insulin delivery.
In February 2020, the FDA classified the action as a Class I recall, the agency’s most serious recall designation, affecting approximately 322,005 devices distributed throughout the United States.
Additional recall notices involving other MiniMed medical products have since been issued, although they involve different alleged defects and safety concerns.
Recalled models include:
- MiniMed 630G (MMT-1715): Devices manufactured and distributed from September 2016 through October 2019.
- MiniMed 670G (MMT-1780): Devices manufactured and distributed from June 2017 through August 2019.
